History
Documents created during the development process.
Background information
-
-
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
-
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix A provisional matrix of stakeholders
-
-
TA225 Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: Appendix B proposal paper presented to the Institute's Guidance Executive
-
-
-
Download PDF version
-
2011/096 NICE recommends new drug for rheumatoid arthritis (PDF 105 KB)
Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: equality impact assessment
-
Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab: equality impact assessment
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final appraisal determination document
-
-
Patient Access Scheme
-
Patient Access Scheme submitted by Merck Sharpe & Dohme (MSD)
-
Patient Access Scheme submitted by Merck Sharpe & Dohme (MSD) (PDF 382 KB)
-
Letter from the Department of Health confirming NICE can consider the Patient Access Scheme
-
-
Report on the additional data and data requested following the second committee meeting produced by the School of Health and Related Research (ScHARR)
-
-
Additional data request
-
NICE request to the manufacturer for additional data
-
NICE request to the manufacturer for additional data (PDF 131 KB)
-
Manufacturer's response to NICE's request for additional data
-
Manufacturer's response to NICE's request for additional data (PDF 218 KB)
-
Response to request for re-modelling and additional information from Merck Sharp & Dohme (MSD)
-
-
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Report on the additional data requested following the ACD produced by the School of Health and Related Research (ScHARR)
-
-
Consultee and commentator comments on the ACD
-
Merck Sharpe & Dohme (MSD)
-
-
British Health Professionals in Rheumatology
-
-
National Rheumatoid Arthritis Society
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
-
Welsh Assembly Government
-
-
Abbott Laboratories
-
-
Pfizer
-
-
Roche Pharmaceuticals
-
-
UCB Pharma
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: appraisal consultation
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: evaluation report
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: pre-meeting briefing
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: evidence review group report
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: clarification
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer's response to clarification
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer response to first clarification
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer response to follow-up clarification
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE clarification letters
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE follow-up clarification letter
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: NICE clarification letter
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: non-manufacturer submissions
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from National Rheumatoid Arthritis Society
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from British Society for Rheumatology
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from Primary Care Rheumatology Society
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from Royal College of Nursing
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from Royal College of Pathologists
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from NHS Dorset
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from NHS North of Tyne working on behalf of Newcastle and North Tyneside Primary Care Trusts and Northumberland Care Trust
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: submission from NHS Torbay
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: manufacturer submission
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert written personal statements
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert personal statement - Deighton
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: expert personal statement - Moots
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final matrix
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final matrix
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: updated final scope April 2010
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: final scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
-
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the draft scope
-
Letter for consultees and commentators on the suspension of this appraisal.
-
Letter for consultees and commentators on the suspension of this appraisal.
-
Letter for consultees and commentators on the suspension of this appraisal. (PDF 21 KB)
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the provisional matrix
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: Institute's response to consultee and commentator comments on the provisional matrix
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: draft scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: draft scope
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: provisional matrix
-
Rheumatoid arthritis (after failure of previous antirheumatic drugs) - golimumab: provisional matrix
-